However, anti-vascular endothelial growth factor (VEGF) and anti-inflammatory pharmaceuticals remain the mainstay of therapy for CNV up to now while there are risks of significant adverse effects (steroid-induced glaucoma; CsA-induced eczema, chest pain, back pain) with these treatments (Roshandel et al., 2018; Zhang et al., 2022). The gene discussed is VEGFA; the disease is Eczematoid dermatitis.